Oral versus nebulized albuterol in the management of bronchiolitis in Egypt

A. M. Gadomski, G. H. Aref, O. B. El Din, I. H. El Sawy, N. Khallaf, Robert E Black

Research output: Contribution to journalArticle

Abstract

The efficacy of albuterol in the management of infants with first-time wheezing is controversial. This double-blind, placebo-controlled trial involved 128 Egyptian infants with first-time wheezing (mean age 5.9 months) who were randomly separated into four equivalent therapy groups: nebulized albuterol, nebulized saline solution, orally administered albuterol, and orally administered placebo. The nebulized therapy groups received two treatments 30 minutes apart; the oral therapy groups received one treatment. In addition, 41 infants with recurrent wheezing comprised an open-label control group who received two albuterol nebulizations. Chest radiographs, leukcoyte counts, blood culture specimens, and nasal aspirate for viral antigen detection were obtained to confirm the clinical diagnosis of viral bronchiolitis. Respiratory and heart rates, clinical score, and oxygen saturation were recorded at baseline and 30 and 60 minutes after treatment. There was no difference among the four randomized groups in any of the outcomes except for an increase in heart rate of 10 beats/min in the nebulized albuterol group compared with a decrease in heart rate of 8 beats/min in the oral placebo group. No differences in the need for additional treatment were observed. Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. We conclude that nebulized albuterol is effective in the treatment of infants with recurrent wheezing, but there was no demonstrable efficacy of orally administered or nebulized albuterol in relieving the respiratory distress of infants with bronchiolitis in Egypt.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalJournal of Pediatrics
Volume124
Issue number1
StatePublished - 1994

Fingerprint

Bronchiolitis
Albuterol
Egypt
Respiratory Sounds
Group Psychotherapy
Heart Rate
Placebos
Respiratory Rate
Viral Bronchiolitis
Therapeutics
Viral Antigens
Nose
Sodium Chloride
Thorax
Oxygen
Control Groups

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gadomski, A. M., Aref, G. H., El Din, O. B., El Sawy, I. H., Khallaf, N., & Black, R. E. (1994). Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. Journal of Pediatrics, 124(1), 131-138.

Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. / Gadomski, A. M.; Aref, G. H.; El Din, O. B.; El Sawy, I. H.; Khallaf, N.; Black, Robert E.

In: Journal of Pediatrics, Vol. 124, No. 1, 1994, p. 131-138.

Research output: Contribution to journalArticle

Gadomski, AM, Aref, GH, El Din, OB, El Sawy, IH, Khallaf, N & Black, RE 1994, 'Oral versus nebulized albuterol in the management of bronchiolitis in Egypt', Journal of Pediatrics, vol. 124, no. 1, pp. 131-138.
Gadomski AM, Aref GH, El Din OB, El Sawy IH, Khallaf N, Black RE. Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. Journal of Pediatrics. 1994;124(1):131-138.
Gadomski, A. M. ; Aref, G. H. ; El Din, O. B. ; El Sawy, I. H. ; Khallaf, N. ; Black, Robert E. / Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. In: Journal of Pediatrics. 1994 ; Vol. 124, No. 1. pp. 131-138.
@article{724ccf32f5214af9a6e6d9b19794e4c8,
title = "Oral versus nebulized albuterol in the management of bronchiolitis in Egypt",
abstract = "The efficacy of albuterol in the management of infants with first-time wheezing is controversial. This double-blind, placebo-controlled trial involved 128 Egyptian infants with first-time wheezing (mean age 5.9 months) who were randomly separated into four equivalent therapy groups: nebulized albuterol, nebulized saline solution, orally administered albuterol, and orally administered placebo. The nebulized therapy groups received two treatments 30 minutes apart; the oral therapy groups received one treatment. In addition, 41 infants with recurrent wheezing comprised an open-label control group who received two albuterol nebulizations. Chest radiographs, leukcoyte counts, blood culture specimens, and nasal aspirate for viral antigen detection were obtained to confirm the clinical diagnosis of viral bronchiolitis. Respiratory and heart rates, clinical score, and oxygen saturation were recorded at baseline and 30 and 60 minutes after treatment. There was no difference among the four randomized groups in any of the outcomes except for an increase in heart rate of 10 beats/min in the nebulized albuterol group compared with a decrease in heart rate of 8 beats/min in the oral placebo group. No differences in the need for additional treatment were observed. Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. We conclude that nebulized albuterol is effective in the treatment of infants with recurrent wheezing, but there was no demonstrable efficacy of orally administered or nebulized albuterol in relieving the respiratory distress of infants with bronchiolitis in Egypt.",
author = "Gadomski, {A. M.} and Aref, {G. H.} and {El Din}, {O. B.} and {El Sawy}, {I. H.} and N. Khallaf and Black, {Robert E}",
year = "1994",
language = "English (US)",
volume = "124",
pages = "131--138",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Oral versus nebulized albuterol in the management of bronchiolitis in Egypt

AU - Gadomski, A. M.

AU - Aref, G. H.

AU - El Din, O. B.

AU - El Sawy, I. H.

AU - Khallaf, N.

AU - Black, Robert E

PY - 1994

Y1 - 1994

N2 - The efficacy of albuterol in the management of infants with first-time wheezing is controversial. This double-blind, placebo-controlled trial involved 128 Egyptian infants with first-time wheezing (mean age 5.9 months) who were randomly separated into four equivalent therapy groups: nebulized albuterol, nebulized saline solution, orally administered albuterol, and orally administered placebo. The nebulized therapy groups received two treatments 30 minutes apart; the oral therapy groups received one treatment. In addition, 41 infants with recurrent wheezing comprised an open-label control group who received two albuterol nebulizations. Chest radiographs, leukcoyte counts, blood culture specimens, and nasal aspirate for viral antigen detection were obtained to confirm the clinical diagnosis of viral bronchiolitis. Respiratory and heart rates, clinical score, and oxygen saturation were recorded at baseline and 30 and 60 minutes after treatment. There was no difference among the four randomized groups in any of the outcomes except for an increase in heart rate of 10 beats/min in the nebulized albuterol group compared with a decrease in heart rate of 8 beats/min in the oral placebo group. No differences in the need for additional treatment were observed. Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. We conclude that nebulized albuterol is effective in the treatment of infants with recurrent wheezing, but there was no demonstrable efficacy of orally administered or nebulized albuterol in relieving the respiratory distress of infants with bronchiolitis in Egypt.

AB - The efficacy of albuterol in the management of infants with first-time wheezing is controversial. This double-blind, placebo-controlled trial involved 128 Egyptian infants with first-time wheezing (mean age 5.9 months) who were randomly separated into four equivalent therapy groups: nebulized albuterol, nebulized saline solution, orally administered albuterol, and orally administered placebo. The nebulized therapy groups received two treatments 30 minutes apart; the oral therapy groups received one treatment. In addition, 41 infants with recurrent wheezing comprised an open-label control group who received two albuterol nebulizations. Chest radiographs, leukcoyte counts, blood culture specimens, and nasal aspirate for viral antigen detection were obtained to confirm the clinical diagnosis of viral bronchiolitis. Respiratory and heart rates, clinical score, and oxygen saturation were recorded at baseline and 30 and 60 minutes after treatment. There was no difference among the four randomized groups in any of the outcomes except for an increase in heart rate of 10 beats/min in the nebulized albuterol group compared with a decrease in heart rate of 8 beats/min in the oral placebo group. No differences in the need for additional treatment were observed. Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. We conclude that nebulized albuterol is effective in the treatment of infants with recurrent wheezing, but there was no demonstrable efficacy of orally administered or nebulized albuterol in relieving the respiratory distress of infants with bronchiolitis in Egypt.

UR - http://www.scopus.com/inward/record.url?scp=0027958490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027958490&partnerID=8YFLogxK

M3 - Article

C2 - 8283363

AN - SCOPUS:0027958490

VL - 124

SP - 131

EP - 138

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -